Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology | 2 | 2016 | 37 | 0.410 |
Why?
|
| Authorship | 1 | 2013 | 12 | 0.400 |
Why?
|
| Scientific Misconduct | 1 | 2013 | 11 | 0.400 |
Why?
|
| Publishing | 1 | 2013 | 41 | 0.390 |
Why?
|
| Internship and Residency | 3 | 2016 | 439 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2005 | 87 | 0.280 |
Why?
|
| Trans-Activators | 2 | 2005 | 139 | 0.260 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 423 | 0.230 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2005 | 18 | 0.230 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 128 | 0.220 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 27 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 34 | 0.210 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 1222 | 0.210 |
Why?
|
| Breast | 1 | 2004 | 87 | 0.200 |
Why?
|
| Hodgkin Disease | 2 | 2019 | 45 | 0.200 |
Why?
|
| Carcinoma | 1 | 2004 | 136 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2002 | 119 | 0.170 |
Why?
|
| Flow Cytometry | 2 | 2020 | 400 | 0.160 |
Why?
|
| Immunoassay | 1 | 1997 | 23 | 0.140 |
Why?
|
| Biostatistics | 1 | 2016 | 6 | 0.130 |
Why?
|
| Chemistry, Clinical | 1 | 2016 | 4 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 203 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2005 | 975 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 500 | 0.100 |
Why?
|
| Job Application | 1 | 2013 | 12 | 0.100 |
Why?
|
| Deception | 1 | 2013 | 8 | 0.100 |
Why?
|
| Publications | 1 | 2013 | 19 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 371 | 0.100 |
Why?
|
| Humans | 13 | 2020 | 53230 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2005 | 3494 | 0.070 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2008 | 6 | 0.070 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2008 | 3 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2008 | 15 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 19 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 2 | 2005 | 89 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 62 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2005 | 533 | 0.060 |
Why?
|
| Aged | 5 | 2019 | 10429 | 0.060 |
Why?
|
| Cyclin D | 1 | 2005 | 18 | 0.060 |
Why?
|
| Janus Kinase 1 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cyclins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 7 | 0.050 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2004 | 13 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2020 | 118 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 1470 | 0.050 |
Why?
|
| Middle Aged | 6 | 2005 | 13419 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 72 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 89 | 0.050 |
Why?
|
| Tyrosine | 1 | 2003 | 92 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 146 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2003 | 59 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2002 | 38 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 110 | 0.050 |
Why?
|
| United States | 1 | 2013 | 5409 | 0.050 |
Why?
|
| Leukemia | 1 | 2002 | 67 | 0.050 |
Why?
|
| Adult | 5 | 2005 | 14534 | 0.050 |
Why?
|
| Axilla | 1 | 2002 | 92 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 188 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2002 | 217 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 228 | 0.040 |
Why?
|
| Female | 5 | 2005 | 28782 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1133 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 868 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2002 | 252 | 0.040 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 1997 | 2 | 0.030 |
Why?
|
| Hemagglutination Tests | 1 | 1997 | 7 | 0.030 |
Why?
|
| Salts | 1 | 1997 | 7 | 0.030 |
Why?
|
| Cell Extracts | 1 | 1997 | 6 | 0.030 |
Why?
|
| Buffers | 1 | 1997 | 12 | 0.030 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1997 | 4 | 0.030 |
Why?
|
| Plastics | 1 | 1997 | 10 | 0.030 |
Why?
|
| Epitopes | 1 | 1997 | 61 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 169 | 0.030 |
Why?
|
| Rabbits | 1 | 1997 | 372 | 0.030 |
Why?
|
| Male | 4 | 2019 | 27435 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 115 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 219 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2003 | 659 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2003 | 1219 | 0.020 |
Why?
|
| Animals | 2 | 2008 | 13526 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 2008 | 12 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 15 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 39 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 38 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 39 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 64 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 252 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2008 | 681 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 571 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 412 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 54 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 93 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2002 | 6 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 187 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 466 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2002 | 120 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2003 | 5595 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 587 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 412 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 87 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 670 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 598 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2002 | 238 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 949 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 477 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 2318 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 2118 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 5982 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 2991 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 2411 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 830 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1232 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 6907 | 0.010 |
Why?
|
| Child | 1 | 2003 | 7379 | 0.010 |
Why?
|